Latest news with #VWD
Globe and Mail
13-05-2025
- Health
- Globe and Mail
Uncontrolled Bleeding Treatment Market Size in 7MM is expected to grow at a decent CAGR by 2032, estimates DelveInsight
DelveInsight's " Uncontrolled Bleeding Market Insights, Epidemiology, and Market Forecast- 2032" report delivers an in-depth understanding of the Uncontrolled Bleeding, historical and forecasted epidemiology as well as the Uncontrolled Bleeding market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. Discover which therapies are expected to grab the Uncontrolled Bleeding Market Share @ Uncontrolled Bleeding Market Outlook Key Takeaways from the Uncontrolled Bleeding Market Report In April 2025, Baxalta Now part of Shire announced a study is to check effectiveness, side effects, and tolerability of vonicog alfa (recombinant von Willebrand factor [rVWF]), with or without ADVATE, in the treatment and control of nonsurgical bleeding events in pediatric participants (less than (<)18 years of age) with severe hereditary von Willebrand disease (VWD). In February 2025, Boehringer Ingelheim conducted a phase III, Case Series Clinical Study of the Reversal of the Anticoagulant Effects of Dabigatran by Intravenous Administration of Idarucizumab (BI 655075) in Patients Treated With Dabigatran Etexilate Who Have Uncontrolled Bleeding or Require Emergency Surgery or Procedures. The increase in Uncontrolled Bleeding Market Size is a direct consequence of the increasing patient population and anticipated launch of emerging therapies in the 7MM. As per DelveInsight analysis, the Uncontrolled Bleeding Market is anticipated to witness growth at a considerable CAGR. The leading Uncontrolled Bleeding Companies such as Boehringer Ingelheim, PhaseBio Pharmceuticals Inc., Novo Nordisk A/S, CSL Behring, Octapharma, Haemostatix Ltd, Bayer, and others. Promising Uncontrolled Bleeding Pipeline Therapies such as Idarucizumab, Bentracimab (PB2452) Infusionm Hydroxyethyl starch 130/0.4, 6 %, BE1116, Octafibrin, Levonorgestrel IUS (Mirena, BAY86-5028), Minisiston (SH D00342A), Vonicog alfa and others. Stay ahead in the Uncontrolled Bleeding Therapeutics Market with DelveInsight's Strategic Report @ Uncontrolled Bleeding Market Outlook Uncontrolled Bleeding Epidemiology Segmentation in the 7MM The epidemiology section of Uncontrolled Bleeding offers insights into both historical and current patient populations, as well as forecasted trends across seven major countries. This section aids in understanding the factors behind present and projected trends through analysis of various studies and input from key opinion leaders. Additionally, this portion of the market report provides information on the diagnosed patient pool, trends, and underlying assumptions. Download the report to understand which factors are driving Uncontrolled Bleeding Epidemiology trends @ Uncontrolled Bleeding Prevalence Uncontrolled Bleeding Drugs Market The Uncontrolled Bleeding Drugs Market is expected to witness substantial growth in the coming years as more targeted therapies receive regulatory approval and enter clinical practice. Additionally, ongoing research efforts aimed at better understanding the molecular mechanisms underlying Uncontrolled Bleeding signaling in Uncontrolled Bleeding are likely to uncover new therapeutic targets and further expand treatment options for patients. Uncontrolled Bleeding Treatment Market Landscape The Uncontrolled Bleeding treatment market landscape has witnessed significant advancements over the past years, with targeted therapies playing a crucial role in improving outcomes for patients. Among these targeted therapies, the emergence of Uncontrolled Bleeding has garnered attention in the medical community, presenting both challenges and opportunities in treatment strategies. To learn more about Uncontrolled Bleeding treatment guidelines, visit @ Uncontrolled Bleeding Treatment Market Landscape Uncontrolled Bleeding Market Outlook The report's outlook on the Uncontrolled Bleeding market aids in developing a comprehensive understanding of historical, current, and projected trends. This is achieved by examining the influence of existing Uncontrolled Bleeding clinical trials, drugs, unmet needs, as well as drivers, barriers, and the demand for advanced technology. This section provides detailed insights into the trends of each marketed Uncontrolled Bleeding drug and late-stage pipeline therapy. Uncontrolled Bleeding Drugs Uptake The drug chapter of the Uncontrolled Bleeding report provides a comprehensive analysis of both marketed drugs and late-stage pipeline drugs for this condition. It delves into the details of Uncontrolled Bleeding clinical trials, pharmacological actions, agreements, collaborations, approvals, patents, and advantages and disadvantages of each drug, as well as the latest news and press releases related to Uncontrolled Bleeding. Major Uncontrolled Bleeding Companies Boehringer Ingelheim, PhaseBio Pharmceuticals Inc., Novo Nordisk A/S, CSL Behring, Octapharma, Haemostatix Ltd, Bayer, and others. Learn more about the FDA-approved drugs for Uncontrolled Bleeding @ Drugs for Uncontrolled Bleeding Treatment Scope of the Uncontrolled Bleeding Market Report Coverage- 7MM Study Period- 2019-2032 Uncontrolled Bleeding Companies- Boehringer Ingelheim, PhaseBio Pharmaceuticals Inc., Novo Nordisk A/S, CSL Behring, Octapharma, Haemostatix Ltd, Bayer, and others Uncontrolled Bleeding Therapies- idarucizumab, Bentracimab (PB2452) Infusion, Hydroxyethyl starch 130/0.4, 6 %, BE1116, Octafibrin, Levonorgestrel IUS (Mirena, BAY86-5028), Minisiston (SH D00342A), Vonicog alfa, and others. Uncontrolled Bleeding Market Dynamics: Uncontrolled Bleeding Market Drivers and Barriers Uncontrolled Bleeding Market Access and Reimbursement, Unmet Needs and Future Perspectives, Uncontrolled Bleeding Clinical Trials Table of Contents 1. Key Insights 2. Uncontrolled Bleeding Executive Summary 3. Uncontrolled Bleeding Competitive Intelligence Analysis 4. Uncontrolled Bleeding: Market Overview at a Glance 5. Uncontrolled Bleeding: Disease Background and Overview 6. Patient Journey 7. Uncontrolled Bleeding Epidemiology and Patient Population 8. Treatment Algorithm, Current Treatment, and Medical Practices 9. Uncontrolled Bleeding Unmet Needs 10. Key Endpoints of Uncontrolled Bleeding Treatment 11. Uncontrolled Bleeding Marketed Products 12. Uncontrolled Bleeding Emerging Therapies 13. Uncontrolled Bleeding: Seven Major Market Analysis 14. Attribute analysis 15. 7MM: Uncontrolled Bleeding Market Outlook 16. Access and Reimbursement Overview of Uncontrolled Bleeding 17. KOL Views 18. Uncontrolled Bleeding Market Drivers 19. Uncontrolled Bleeding Market Barriers 20. Appendix 21. DelveInsight Capabilities 22. Disclaimer 23. About DelveInsight About Us DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve. Media Contact Company Name: DelveInsight Business Research LLP Contact Person: Yash Bhardwaj Email: Send Email Phone: 09650213330 Address: 304 S. Jones Blvd #2432 City: Las Vegas State: NV Country: United States Website:
Time of India
09-05-2025
- Health
- Time of India
Govt hosp performs C-section on woman with rare disease
Mangaluru: Government Lady Goschen Hospital here has successfully performed surgery on a pregnant woman suffering from life-threatening haemophilia, giving a new lease of life to both mother and woman, who inherited Von Willebrand Disease (VWD), a bleeding disorder, had received treatment at a private hospital since childhood. After getting married, she conceived but faced the risk of bleeding due to haemophilia during pregnancy, which could be disease is primarily caused by a deficiency of Factor VIII, which is crucial in stopping bleeding. This factor needs to be artificially administered regularly. Unfortunately, treatment for this rare condition, affecting one in a lakh, is not easily accessible, and the injections derived from plasma are expensive. Operation Sindoor PM Modi meets NSA, chiefs of armed forces amid spike in tensions with Pak India's air defence systems shoot down Pak drones in J&K, Punjab & Rajasthan Several airports in India to be closed till May 15 - check list The costs proposed by private hospitals were beyond her expectations. In such cases, maternal death is almost medical superintendent Dr Durgaprasad MR said despite understanding the seriousness of her condition, the woman, caught in a dilemma due to family reasons, was determined to become a mother, even at the cost of her life. "Her relatives consulted Dr Sharath Kumar at Wenlock Blood Bank about the supply of Factor VIII injections . Given the complexity of her pregnancy, Government Lady Goschen Hospital took on the challenge of ensuring the safety of both mother and child. The govt arranged for the weekly administration of the necessary injections throughout her pregnancy. She was admitted to the hospital 20 days before her expected delivery date, and a caesarean section was safely performed with all preparations in place. The govt provided 25,000 units of this rare and expensive injection during her care," Dr Durgaprasad and gynaecologists Dr Anupama Rao, Dr Siriganesh, Dr Namitha, anaesthetists Dr Sumesh Rao, Dr Ranjan, and the nursing staff at the hospital helped in the task. After about 10 days of postnatal care, the woman returned home.
